CN1CC(c2ccccc2)Oc2nc(Cl)ccc2C1=O.Nc1ccc(-n2ccnc2)cc1>CC(=O)O.CC(=O)O.COCCOC.O=C([O-])[O-].[Cs+].[Cs+].[Pd].c1ccc(-c2ccccc2P(C2CCCCC2)C2CCCCC2)cc1>CN1CC(c2ccccc2)Oc2nc(Nc3ccc(-n4ccnc4)cc3)ccc2C1=O8-chloro-4-methyl-2-phenyl-3,4-dihydropyrido[3,2-f][1,4]oxazepin-5(2H)-one (115 mg, 0.40 mmol), 4-(1H-imidazol-1-yl)aniline (95 mg, 0.60 mmol), PdOAc2 (8.94 mg, 0.04 mmol), biphenyl-2-yldicyclohexylphosphine (13.96 mg, 0.04 mmol) and CS2CO3 (389 mg, 1.19 mmol) were placed in a microwave vial equipped with a stirring bar. The vial was capped and flushed with argon. DME (1.5 mL) was added via a syringe and the mixture was heated to 100°C in a microwave apparatus for 1 h. The residue was diluted with ethyl acetate and filtered through a short plug og Celite. The filtrate was evaporated and the residue was purified by HPLC to give 62 mg of the product as a solid.
Loading…
